Study to measure biomarkers of collagen breakdown in COPD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00020343

Enrollment

120

Registered

2019-12-30

Start date

2020-02-27

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

J44.9 J45.9

Interventions

Group 1: Patients will be characterized according to clinically symptoms pulmonary functional assessments as well as assessements of sputum and total blood count at one visit day.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: COPD: - established diagnosis of COPD - GOLD stage 1-3 - at least 10 py of smoking Asthma: - established diagnosis of asthma - GINA 4 and 5 (at least medium-high dose of ICS/LABA combination) Controls: - no chronic lung disease - no inhaled medication - for (ex-)-smoking controls: at least 10 py of smoking

Exclusion criteria

Exclusion criteria: COPD: - respiratory tract infection or exacerbation within the last 4 weeks - FEV1 less than 30% - autoimmune disease that could affect collagen breakdown asthma: - respiratory tract infection or exacerbation within the last 4 weeks - FEV1 less than 30% - autoimmune disease that could affect collagen breakdown controls: - respiratory tract infection within the last 4 weeks - autoimmune disease that could affect collagen breakdown

Design outcomes

Primary

Measure	Time frame
Measurement of biomarkers of collagen breakdown	—

Secondary

Measure	Time frame
Association of biomarkers with indeces of disease severity (lung function, clinical phenotype)	—

Countries

Germany

Contacts

Public ContactHenrik Watz

Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf

h.watz@pulmoresearch.de0049-410288810

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026